[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100586080":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":33,"responsibleParty":48,"collaborators":20,"id":50,"slug":20,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":51,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":20,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":36,"whyStopped":20,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"liver transplant patients","EXPERIMENTAL","Liver transplantation performed after selective internal radiotherapy (SIRT) with Yttrium-90 and chemotherapy in patients with locally advanced (unresectable but non-metastatic) intrahepatic cholangiocarcinoma.",[13],"Procedure: Liver transplant",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"PROCEDURE","Liver transplant","follow-up of liver transplant patients after selective internal radiotherapy (SIRT) with Yttrium-90 and chemotherapy",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Mohamed Bouattour","APHP","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Mohamed BOUATTOUR","CONTACT","1.40.87.56.14","+33","mohamed.bouattour@aphp.fr",[34],{"facility":35,"status":36,"city":37,"state":20,"zip":20,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Beaujon","RECRUITING","Clichy-sous-Bois","France","FR",{"type":41,"coordinates":42},"Point",[43,44],2.55323,48.9102,{"lat":44,"lon":43},[47],{"name":28,"role":29,"phone":20,"phoneExt":20,"email":32},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100586080",false,"NCT06910722","Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy","Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After Selective Internal Radiotherapy With Labeled Yttrium and Chemotherapy: a Phase 2 Study","RIS-TH","Inclusion Criteria:\n\n* Patient aged 18 to 65\n* With histologically documented intrahepatic cholangiocarcinoma (primary diagnosis):\n\n  * Uni or pauci nodular (≤ 5 lesions (all lesions are counted, even those less than 1 cm))\n  * Without extrahepatic or lymph node involvement\n  * Technically unresectable R0 according to an expert panel\n* Tumor target \\> 2 cm\n* WHO 0-1\n* free and informed consent signed\n* highly effective contraception for men and women of childbearing age during study participation up to 2 years post TH\n\nExclusion Criteria:\n\n* Extrahepatic, vesicular or perihilar cholangiocarcinoma\n* Tumor infiltration of more than 50% of the liver\n* Mixed cholangiocarcinoma, hepatocellular carcinoma, fibrolamellar carcinoma\n* Previous treatment for CCI\n* Cirrhosis ≥ Child B7\n* Chronic alcoholism\n* Uncontrolled chronic active infections (patients with HBV, HCV or HDV infections may be included if infections are controlled)\n* Stage III A, IIIB, IV and V chronic renal failure (glomerular filtration rate 59 ml\u002Fmin)\n* Contraindications to liver transplant\n\n  * Severe untreatable conditions\n  * Recent history (less than 5 years) of cancer\n  * severe comorbidities\n  * Psychiatric or psychological disorders\n* Pregnant or breast-feeding women\n* Patient under guardianship\n* Not affiliated to a Health care system\n* Participating in another interventional study or within the exclusion period of a previous study involving the human body","ALL","18 Years","65 Years",{"count":61,"type":62},36,"ESTIMATED","INTERVENTIONAL",[65],"NA","The study hypothesis is that liver transplantation after selective internal radiation therapy (SIRT) and chemotherapy would improve 3-year overall survival in patients with locally advanced (unresectable but non-metastatic) intrahepatic cholangiocarcinoma.\n\nIt is planned to include 36 patients with locally advanced intrahepatic cholangiocarcinoma, not eligible for initial surgery and without metastases. Participants will be recruited from care facilities in France.",[68,69],"Intrahepatic Cholangiocarcinoma","Locally Advanced Intrahepatic Cholangiocarcinoma",[71,72,73],"liver transplantation","locally advanced intrahepatic cholangiocarcinoma","selective internal radiation therapy","2026-04-02",{"date":76,"type":77},"2026-04-06","ACTUAL",{"date":79,"type":77},"2025-08-28",{"date":81,"type":62},"2034-10-01",{"name":5,"class":6},1]